Immunotherapy
Conference Coverage
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphoma
LUGANO, SWITZERLAND – The overall response rate with the combination was 65%, including 50% complete responses, in 20 patients with relapsed...
Conference Coverage
Studies provide insight into link between cancer immunotherapy and autoimmune disease
MADRID – Patients may “require much higher doses – of steroids in particular – to treat their symptoms.”
Conference Coverage
VIDEO: Immune therapy effective, durable in treatment-naive melanoma brain metastases
CHICAGO – For patients with asymptomatic brain metastases from melanoma who had not had prior treatment, nivolumab combined with ipilimumab...
Conference Coverage
VIDEO: Combined immunotherapy strategy shows promise in advanced solid tumors
CHICAGO – IgG1 agonist monoclonal antibody plus nivolumab induced durable partial responses in patients with tumors thought to be insensitive to...
Conference Coverage
Immune-agonist combo has activity against several tumor types
CHICAGO – How can we improve responses in heavily pretreated patients with a variety of tumor types?
Case Reports
Palmoplantar exacerbation of psoriasis after nivolumab for lung cancer
News
FDA approves pembrolizumab for first-line advanced NSCLC
The approval was based on an improved overall response rate and progression-free survival in a cohort of 123 patients.
Conference Coverage
Flu shots may spark immune adverse events in PD-1 blockade for NSCLC
GENEVA – More than half of patients who had received a trivalent influenza vaccine in a small study had immune-related adverse events.
Conference Coverage
Modifying CAR-T with IL-15 improved activity in glioma models
Adding an immunostimulatory cytokine to CAR-T improved the adaptive immunotherapy’s activity against aggressive pediatric brain malignancies.
Conference Coverage
VIDEO: Blinatumomab, inotuzumab reshape relapsed ALL treatment
Blinatumomab and inotuzumab have dramatically changed treatment for patients with acute lymphoblastic leukemia to prepare them for a stem cell...
Conference Coverage
Atezolizumab improved survival in triple-negative breast cancer
In a phase I trial, the immunotherapy agent atezolizumab improved survival in triple-negative breast cancer.